ES2190241T3 - Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas. - Google Patents

Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas.

Info

Publication number
ES2190241T3
ES2190241T3 ES99941418T ES99941418T ES2190241T3 ES 2190241 T3 ES2190241 T3 ES 2190241T3 ES 99941418 T ES99941418 T ES 99941418T ES 99941418 T ES99941418 T ES 99941418T ES 2190241 T3 ES2190241 T3 ES 2190241T3
Authority
ES
Spain
Prior art keywords
composition
powder
active substance
sieve
therapeutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99941418T
Other languages
English (en)
Inventor
Poul Bertelsen
Nils Gjerl V Hansen
Hermann Ruckendorfer
Shigeru Itai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Application granted granted Critical
Publication of ES2190241T3 publication Critical patent/ES2190241T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuesto farmacéutico de liberación rápida para administración oral, que comprende una substancia terapéutica y/o profilácticamente activa, cuya substancia activa queda definida por una de las características i) o ii): i) la substancia activa tiene una solubilidad máxima de 0, 1 % peso/volumen en ácido clorhídrico 0, 1 N a temperatura ambiente; ii) la substancia activa tiene un valor pKa máximo de 5, 5, y en el que el compuesto farmacéutico de liberación rápida tiene además una de las características iii) o iv): iv) el compuesto farmacéutico de liberación rápida se basa en un material en polvo que comprende la substancia terapéutica y/o profilácticamente activa y que tiene un tamaño de partículas que, cuando el material en polvo es sometido a análisis de cribado, como mínimo, 90 % peso/peso de las partículas atraviesan una criba de 180 µm, estableciendo contacto el material en polvo con un medio acuoso para formar un compuesto en partículas, que tiene un tamaño de partículas tal que, cuando el compuesto en partículas es sometido a análisis de cribado, entonces un mínimo de 50 % peso/peso de las partículas atraviesan una criba de 180 µm; iv) el compuesto farmacéutico de liberación rápida adopta la forma de compuesto en partículas o se basa en un compuesto en partículas, que es obtenido por contacto de un material en polvo que comprende la substancia terapéutica y/o profilácticamente activa con un medio acuoso de manera tal que el tamaño medio de partículas del compuesto es como máximo 100 % superior al tamaño medio de partículas del material en polvo antes de contacto con el medio acuoso, y en el que el compuesto farmacéutico de liberación rápida es tal que la substancia activa recibe el contacto de una substancia alcalina, y en el que el compuesto farmacéutico de liberación rápida, una vez comprobada de acuerdo con el método de disolución I que se ha definido utilizando ácido clorhídrico 0, 07 N como medio de disolución, libera un mínimo de 50 % peso/peso de la substancia activa dentro de los primeros 20 minutos de la prueba.
ES99941418T 1998-09-10 1999-09-10 Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas. Expired - Lifetime ES2190241T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199801143 1998-09-10

Publications (1)

Publication Number Publication Date
ES2190241T3 true ES2190241T3 (es) 2003-07-16

Family

ID=8101500

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99941418T Expired - Lifetime ES2190241T3 (es) 1998-09-10 1999-09-10 Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas.

Country Status (13)

Country Link
US (1) US6713089B1 (es)
EP (1) EP1109534B1 (es)
JP (2) JP5026635B2 (es)
AT (1) ATE232382T1 (es)
AU (1) AU5504599A (es)
CA (1) CA2343148C (es)
DE (1) DE69905380T2 (es)
DK (1) DK1109534T3 (es)
EA (1) EA004032B1 (es)
ES (1) ES2190241T3 (es)
PT (1) PT1109534E (es)
TR (1) TR200100708T2 (es)
WO (1) WO2000015195A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030161875A1 (en) * 2002-02-27 2003-08-28 Deepak Murpani Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2005004915A2 (en) * 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PL1916994T3 (pl) * 2004-06-29 2014-05-30 Takeda Pharma As Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
JP5490347B2 (ja) * 2005-05-27 2014-05-14 エスエス製薬株式会社 経口投与用製剤
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
AU2006271150A1 (en) 2005-07-20 2007-01-25 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2007130507A2 (en) * 2006-05-03 2007-11-15 Proethic Pharmaceuticals, Inc. Acute pain medications based on fast acting diclofenac-opioid combinations
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
WO2008062449A2 (en) * 2006-09-18 2008-05-29 Glenmark Pharmaceuticals Limited A novel pharmaceutical soft gel composition containing dexibuprofen and paracetamol
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
ES2560899T3 (es) 2007-09-14 2016-02-23 Wockhardt Limited Composiciones de diacereína
ES2590604T3 (es) * 2008-01-04 2016-11-22 Schabar Research Associates Llc Composición que comprende un analgésico y un antihistamínico
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
EP2291084A4 (en) 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
KR20120030106A (ko) 2009-06-25 2012-03-27 아스트라제네카 아베 Ｎｓａｉｄ-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ES3037313T3 (en) 2009-10-12 2025-09-30 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
MX2012010077A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Uso de meloxicam para el tratamiento a largo plazo de trastornos musculoesqueleticos en gatos.
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
WO2012146314A1 (en) 2011-04-29 2012-11-01 Refarmed Chemicals Sa Thin gelatin capsules for rapid drug release in the mouth
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP2012012411A (ja) * 2011-10-03 2012-01-19 Ssp Co Ltd 経口投与用製剤
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
JP2013216701A (ja) * 2013-07-29 2013-10-24 Ssp Co Ltd 経口投与用製剤
WO2015016256A1 (ja) * 2013-07-30 2015-02-05 ライオン株式会社 錠剤
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016004170A1 (en) 2014-07-03 2016-01-07 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
JP6983161B2 (ja) 2015-09-15 2021-12-17 プラクシス・バイオリサーチ・エルエルシー フェンカンファミンのプロドラッグ
WO2018197932A1 (en) 2017-04-27 2018-11-01 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of ketorolac
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
JP7170437B2 (ja) * 2018-06-29 2022-11-14 小林製薬株式会社 内服用医薬組成物
EP3856160A4 (en) 2018-09-25 2022-07-06 SpecGx LLC ABUSE-PROOF IMMEDIATE RELEASE CAPSULE DOSAGE FORMS
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
JP7499025B2 (ja) * 2019-12-27 2024-06-13 小林製薬株式会社 内服用医薬組成物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
KR20230051164A (ko) 2020-07-15 2023-04-17 샤바르 리서치 어소시에이츠 엘엘씨 급성 통증의 치료 및 속쓰림의 중증도 및/또는 위험의 감소를 위한 이부프로펜 및 파모티딘으로 구성된 단위 경구 투여 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965072A (en) * 1988-11-03 1990-10-23 Miles Inc. Granulating composition and method
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
JP2906528B2 (ja) * 1990-02-14 1999-06-21 大正製薬株式会社 吸収を促進した内服用固形製剤
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
ATE216577T1 (de) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
EP0760680A1 (en) 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmaceutical composition
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
AU5504599A (en) 2000-04-03
CA2343148A1 (en) 2000-03-23
PT1109534E (pt) 2003-06-30
US6713089B1 (en) 2004-03-30
DK1109534T3 (da) 2003-06-10
ATE232382T1 (de) 2003-02-15
EP1109534B1 (en) 2003-02-12
JP2002524492A (ja) 2002-08-06
JP2012082197A (ja) 2012-04-26
DE69905380D1 (de) 2003-03-20
DE69905380T2 (de) 2003-11-27
EP1109534A1 (en) 2001-06-27
JP5622703B2 (ja) 2014-11-12
EA200100331A1 (ru) 2001-08-27
WO2000015195A1 (en) 2000-03-23
EA004032B1 (ru) 2003-12-25
TR200100708T2 (tr) 2001-07-23
JP5026635B2 (ja) 2012-09-12
CA2343148C (en) 2005-11-15

Similar Documents

Publication Publication Date Title
ES2190241T3 (es) Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas.
ES2543427T3 (es) Forma farmacéutica oral de deferasirox
DE69934135D1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
EA200601588A1 (ru) Стабилизированные перенасыщенные твёрдые растворы липофильных лекарственных средств
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
SK5672001A3 (en) Improved fast disintegrating tablet
DK1441704T3 (da) Orodispersibel tablet med höj homogenitet og fremgangsmåde til fremstilling heraf
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
NO20001670L (no) Fremgangsmate for fremstilling av en smaksmaskert farmasoytisk blanding og smaksmaskert farmasoytisk blanding fremstilt ifolge denne fremgangsmaten, samt smaksmaskerte tyggbare tabletter
HUP9801615A2 (hu) Szimetikon/vízmentes kalcium-foszfát-kompozíciók
JPS61251617A (ja) １つ又はそれ以上の活性成分を液に調整放出する組成物及びその調整方法
KR20000048819A (ko) 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
RS62505B1 (sr) Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
KR960021061A (ko) 경구 투여용 약제학적 조성물
Zimm et al. Drug release from a multiparticulate pellet system
EE200000186A (et) Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
Kuno et al. Effect of preparation method on properties of orally disintegrating tablets made by phase transition
JP2000119175A (ja) 口腔内速崩壊性固形製剤
Gordon et al. The effect of aging on the dissolution of wet granulated tablets containing super disintegrants
Jacob et al. Preparation and evaluation of microencapsulated fast melt tablets of ambroxol hydrochloride
JP6308938B2 (ja) 粒状物を製造する方法
Usmani et al. Development and evaluation of orally disintegrating tablets of montelukast sodium by direct compression method
Guo et al. Investigation of the release of aspirin from spray-congealed micro-pellets
ITMI20010907A1 (it) Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi